$ALC

Alcon has warned that a US proposal may lead companies to leave Europe. Novo Holdings and international funds are investing DKK 60 million in a new Danish biotech company, highlighting growth potential in the sector.

Bill Ackman's Pershing Square increased stakes in Visa, Mastercard, Netflix, S&P Global, Intercontinental Exchange, and Alcon, while reducing Amazon and exiting Alphabet. Ackman believes these companies will benefit from AI, citing their proprietary data and strong market positions. Pershing Square reported a -12.6% return in the first half of 2026, lagging the S&P 500. Intercontinental Exchange reported $2.7B in Q2 revenue and raised full-year guidance.

Optometrist Malik shares her experience with toric contact lenses, emphasizing patient feedback and lifestyle conversations to identify suitable candidates. She encourages practitioners to ask questions and involve the entire practice team in the process. Malik also highlights the importance of early introduction of toric lenses for better patient adaptation. Alcon's WATERINNOVATIONS toric portfolio now supports a broader range of astigmatic patients with extended parameters.

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

President Trump secured drug pricing agreements with nine pharma firms, including Alcon, Astellas, Teva, and UCB, bringing the total to 26 firms representing 90% of the US market. The deals require Medicaid discounts and $19.6B in US manufacturing investments. The White House estimates $529B in economic savings over a decade.

Alcon (SIX/NYSE: ALC) launched UNITY M, a premium ophthalmic microscope with advanced visualization and modular upgrades. The product will begin commercial rollout in the U.S. and Japan later this year, with additional markets to follow. UNITY M is designed for surgical precision and customization, featuring a stable red reflex and color tunable illumination. The microscope has received regulatory approvals in several regions, including the U.S. and Europe.

Nine drugmakers (Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, UCB) joined Medicaid pricing deals, covering 89% of branded drug market. Savings estimated at $600B over a decade, per the White House. Medicaid copays likely unchanged. Companies to invest $19.6B in U.S. manufacturing and donate drug ingredients.

President Trump announced agreements with nine pharmaceutical companies to lower U.S. drug prices to match the lowest prices paid by other developed nations. The deals cover 89% of the branded drug market and include investments in U.S. manufacturing and donations to the Strategic Active Pharmaceutical Ingredients Reserve. Companies involved include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements aim to save American

President Trump announced nine new drug pricing deals with pharmaceutical companies, including Teva Pharmaceuticals and Sun Pharma, under the MFN framework. The agreements cover 89% of the branded drug market and aim to reduce prices for treatments of chronic and rare diseases. The deals are projected to save $600 billion over a decade, with $700 million already saved since February 2026. Companies also pledged $19.6 billion in U.S. manufacturing investments and contributions to the SAPIR.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.